Session 5: The CML frontier
Chair: Dr David Yeung

• Making TFR Mainstream
  (Prof. Tim Hughes)
• Prognostic biomarkers in CML
  (Prof. Deborah White)
• The immunology of CML and immunomodulation
  (A/Prof Agnes Yong)

Making TFR mainstream
Prof Timothy Hughes, SAHMRI / University of Adelaide & South Australia

• The TFR journey
• Is it truly safe? What are the known and unknown risks?
• EURO-SKI study
• TKI treatment and MR⁴ duration
• Institutional requirements for safe supervision of TFR
• TFR recommendations including patient cases
• Conclusions
• TARGET - Real world data on treatment discontinuation

Prognostic biomarkers in CML
Professor Deborah White, SAHMRI

• Predictive biomarkers
• Chemokines, cytokines and growth factors
• KIR genotypes
• CIP2A
• Drug transporters
• Genomics
• Drug monitoring and compliance
• Summary

Immunology of CML and Immunomodulation
A/Prof. Agnes Yong - SAHMRI / University of Adelaide

• The graft versus leukemia effect
• Are leukemia-associated antigen specific T cells relevant in CML?
• Are NK cells important in CML disease control?
• Are immune suppressors T rep and MDSs relevant?
• Are B cells important in CML?
• Immune predictors of TFR success
• Can TFR success be improved by immunomodulation?
• Summary